pharmaphorum1d
BridgeBio poised to challenge Pfizer after Attruby approval
BridgeBio is pointing to the approved indication for Attruby as it gears up to launch the drug with a list price of $18,759 for a 28-day supply, saying it is the only drug with a label that says ...
ETF Daily News6d
BridgeBio Pharma (NASDAQ:BBIO) Receives FDA Approval for ATTR-CM Treatment ‘Attruby™ (acoramidis)’
Attruby will be available at a recommended dose of 712 mg, taken twice daily, at a list price of $18,759.12 for a 28-day ...
Drug acoramidis to treat rare heart disease approved by FDA
The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed ...
Business Insider6d
BridgeBio Pharma Receives Buy Rating Following Attruby’s FDA Approval and Strategic Milestones
Don't Miss our Black Friday Offers: Mani Foroohar has given his Buy rating due to a combination of factors including the recent FDA approval of BridgeBio Pharma’s drug Attruby for treating ...
STAT5d
BridgeBio wins FDA approval for heart disease drug
The drug, known scientifically as acoramidis, will be sold by BridgeBio under the brand name Attruby. The FDA cleared Attruby to treat patients with the heart condition known as transthyretin ...
BioSpace6d
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
A Short Lesson in Drug Competition
See the new treatment that will break a Pfizer monopoly on a drug for heart disease.
The Pharma Letter2d
The week in pharma: action, reaction and insight – week to November 29
Among important regulatory news last week, US drugmaker BridgeBio Pharma gained Food and Drug Administration (FDA) approval ...